Awada, Ahmad and Colomer, Ramon and Inoue, Kenichi and Bondarenko, Igor and Badwe, Rajendra A. and Demetriou, Georgia and Lee, Soo-Chin and Mehta, Ajay O. and Kim, Sung-Bae and Bachelot, Thomas and Goswami, Chanchal and Deo, Suryanarayan and Bose, Ron and Wong, Alvin and Xu, Feng and Yao, Bin and Bryce, Richard and Carey, Lisa A. (2016) Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA Oncology, 2 (12). pp. 1557-1564. ISSN 2374-2437 (Print) ; 2374-2445 (Electronic) ; 2374-2437 (Linking)
|
Text
Original Investigation.pdf Download (596kB) | Preview |
Abstract
Abstract Importance Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed. Objective To determine whether neratinib, an irreversible pan-ERBB tyrosine kinase inhibitor, plus paclitaxel improves progression-free survival compared with trastuzumab plus paclitaxel in the first-line treatment of recurrent and/or metastatic ERBB2-positive breast cancer. Design, Setting, and Participants In the randomized, controlled, open-label NEfERT-T trial conducted from ...
| Item Type: | Article |
|---|---|
| Additional Information: | doi:10.1001/jamaoncol.2016.0237 http://jamanetwork.com/journals/jamaoncology/article-abstract/2513249 |
| Subjects: | Oncology |
| Divisions: | Departments > Department of Oncology and Medical Radiology |
| Depositing User: | Елена Шрамко |
| Date Deposited: | 21 Sep 2017 08:17 |
| Last Modified: | 21 Sep 2017 08:17 |
| URI: | http://repo.dma.dp.ua/id/eprint/1963 |
Actions (login required)
 |
View Item |
